Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04373460 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
A Phase 2 study of SARS-CoV-2, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,225
- Enrollment target
- 20
- Study locations
NCT04373460: Completed Phase 2 study of SARS-CoV-2, sponsored by Johns Hopkins University.
NCT04373460 is a Phase 2 study of SARS-CoV-2 that has completed, run by Johns Hopkins University. The registered enrollment target is 1,225 participants, below the 3,418-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04373460, a Phase 2 study of SARS-CoV-2, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,225 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
Primary Outcome
Cumulative Number measured as the proportion of subjects who were hospitalized or who died prior to hospitalization
Conditions Studied
Interventions
- BIOLOGICAL SARS-CoV-2 convalescent plasma
- BIOLOGICAL Plasma from a volunteer donor
Study Locations (20)
Arizona
- Center for American Indian Health - Chinle Office - Chinle
- Mayo Clinic, Phoenix - Phoenix
- University of Arizona, Phoenix - Tucson
- University of Arizona, Tuscon - Tucson
- Center for American Indian Health - Whiteriver Office - Whiteriver
Maryland
- Anne Arundel Medical Center - Annapolis
- The Johns Hopkins University - Baltimore
- MedStar Washington Hospital Center - Hyattsville
California
- University of California, Los Angeles - Los Angeles
- University of California, Irvine Health - Orange
Connecticut
- Western Connecticut Health Network, Danbury Hospital - Danbury
- Western Connecticut Health Network, Norwalk Hospital - Norwalk
Florida
- University of Miami - Coral Gables
- University of Miami Clinical Translational Research Site - Miami
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- NorthShore University HealthSystem - Evanston
Louisiana
- Tulane University - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,225 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
What the finished NCT04373460 record still lists
NCT04373460 is an interventional study that assigns participants to a tested intervention. Its 1,225 participants enrollment target places it among the larger protocols in the corpus, below the 3,418-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (64% lower).
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 2 interventions - of which SARS-CoV-2 convalescent plasma is the first listed.
NCT04373460 names 20 study sites across 11 states, led by Arizona, Maryland, California.
Frequently Asked Questions
What is clinical trial NCT04373460 about?
NCT04373460 is a clinical study titled "Convalescent Plasma to Limit SARS-CoV-2 Associated Complications". To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
What is the current status of trial NCT04373460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,225 participants. The study started on 2020-06-03. Estimated completion is 2022-12-14.
What conditions does trial NCT04373460 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT04373460?
The interventions under investigation include: SARS-CoV-2 convalescent plasma (BIOLOGICAL), Plasma from a volunteer donor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04373460?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04373460 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04373460's enrollment target sits among peer trials
1,225 7th of 34 higher than 28 of 34 other SARS-CoV-2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV-2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 2
-
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
COMPLETED · Phase 2
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI